Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study.

[1]  T. Therneau,et al.  Chemotherapy for hormonally refractory advanced prostate carcinoma. A Comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5‐fluorouracil , 1992, Cancer.

[2]  M. Eisenberger.  Chemotherapy for prostate carcinoma. , 1988, NCI monographs : a publication of the National Cancer Institute.

[3]  K. A. Forbes,et al.  Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Brady,et al.  A reexamination of the stable category for evaluating response in patients with advanced prostate cancer , 1984, Cancer.

[5]  H. Scher,et al.  Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. , 1984, The Journal of urology.

[6]  L. Heilbrun,et al.  Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Babaian,et al.  Chemotherapy of hormone-refractory carcinoma of prostate with 5-fluorouracil, adriamycin, and mitomycin C. , 1984, Urology.

[8]  K. A. Forbes,et al.  Treatment of hormone-resistant metastatic carcinoma of the prostate with 5-FU, doxorubicin, and mitomycin (FAM'): a preliminary report. , 1983, Cancer treatment reports.

[9]  F. Freiha,et al.  Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Logothetis,et al.  Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Logothetis,et al.  Doxorubin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: A preliminary report , 1982 .

[12]  B. Levin,et al.  5‐Fluorouracil, adriamycin, and mitomycin‐C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas , 1980, Cancer.

[13]  B. Hoogstraten,et al.  Dose response evaluation of adriamycin in human neoplasia , 1977, Cancer.

[14]  G. Bonadonna,et al.  Phase II evaluation of adriamycin in human neoplasia , 1973, Cancer.

[15]  I. Bross,et al.  Effects of 5-fluorouracil (NSC-19893) in 389 patients with cancer. Eastern Clinical Drug Evaluation Program. , 1968, Cancer chemotherapy reports.

[16]  J. M. Schroeder,et al.  Five years clinical experience with 5-fluorouracil. , 1962, JAMA.

[17]  Hall Be,et al.  Treatment of far-advanced cancer with 5-fluorouracil, used alone and in combination with irradiation. Incidence and duration of remission and survival-time data in 223 patients. , 1962 .

[18]  R. Ausman,et al.  An evaluation of actinomycin D and mitomycin C in patients with advanced cancer. , 1961, Surgery.

[19]  A. Weiss,et al.  An evaluation of 5-fluorouracil in malignant disease. , 1961, Annals of internal medicine.